🇺🇸 US

NBIX revenue, net income and debt history (Neurocrine Biosciences Inc)

Quick answer

Neurocrine Biosciences Inc (NBIX) reported revenue of $2.86B and net income of $478.6M for the fiscal year ended 2025-12-31, up 21.4% from $2.36B the year before, per its 10-K filed with the SEC on 2026-02-11.

✓ SEC EDGAR XBRL company facts (10-K/10-Q filings)

Data as of 2025-12-31. Source: SEC EDGAR XBRL company facts (10-K/10-Q filings)

Fiscal yearRevenueNet incomeLong-term debt
2025 (FY ending 2025-12-31)$2.86B$478.6M—
2024 (FY ending 2024-12-31)$2.36B$341.3M—
2023 (FY ending 2023-12-31)$1.89B$249.7M—
2022 (FY ending 2022-12-31)$1.49B$154.5M—
2021 (FY ending 2021-12-31)$1.13B$89.6M—
2020 (FY ending 2020-12-31)$1.05B$407.3M—
2019 (FY ending 2019-12-31)$788.1M$37.0M—
2018 (FY ending 2018-12-31)$451.2M$21.1M—
2017 (FY ending 2017-12-31)$161.6M-$142.5M—
2016 (FY ending 2016-12-31)$15.0M-$141.1M—

Related

Last updated 2026-10-16. Data only, not financial or tax advice.